


WHAT IS CLAIMED IS:

1. A compound having the Formula I:




I

or a pharmaceutically acceptable salt, or solvate thereof, wherein:

*n* is an integer from 1 to 2;

R<sub>1</sub> is selected from the group consisting of:

(i)



where Y is alkylene, and

R<sub>3</sub> and R<sub>4</sub> are the same or different and are selected from hydrogen, alkyl, or aryl, or R<sub>3</sub> and R<sub>4</sub> together form an alkylene chain having 4 to 5 carbon atoms optionally interrupted by a nitrogen or oxygen;


(ii) pyridylalkyl; and

(iii) piperidin-4-yl, optionally substituted by alkyl, aryl or aralkyl; and

R<sub>2</sub> is selected from the group consisting of:


- (i) optionally substituted phenoxyphenyl;
- (ii) optionally substituted phenylthiophenyl;
- (iii) optionally substituted benzyloxyphenyl;
- (iv) optionally substituted benzylthiophenyl;

(v)




wherein  $R_6$  and  $R_7$  are independently hydrogen or alkyl; and  $p$  and  $q$  are integers from 0 to 4;

(vi)



wherein  $R_8$  is hydrogen, halogen or alkyl;


(vii)



wherein  $R_9$  is hydrogen or alkyl; and

(viii) naphthalenyl.


2. The compound according to claim 1, wherein  $R_1$  is



and  $Y$  is ethylene or propylene.

3. The compound according to claim 1, wherein  $R_1$  is

(i)




where  $R_3$  and  $R_4$  together form an alkylene chain having 4 to 5 carbon atoms;  $Y$  is an optionally substituted  $C_{1-6}$  alkylene chain; and

$R_2$  is phenoxyphenyl or benzyloxyphenyl, wherein the phenoxy moiety is optionally substituted with alkyl, halogen or haloalkyl.

4. The compound according to claim 3, wherein  $R_3$  and  $R_4$  together form an alkylene chain of 5 carbon atoms; and  $Y$  is an optionally substituted  $C_{2-4}$  alkylene chain.

5. The compound according to claim 3, wherein  $R_3$  and  $R_4$  together form an alkylene chain of 4 carbon atoms, and  $Y$  is an optionally substituted  $C_{2-4}$  alkylene chain.

6. The compound according to claim 1, wherein  $R_1$  is



where  $R_3$  and  $R_4$  are independently hydrogen, alkyl or alkylenearyl,  $Y$  is an optionally substituted  $C_{1-4}$  alkylene chain; and

$R_2$  is phenoxyphenyl or benzyloxyphenyl, wherein the phenoxy moiety is optionally substituted with alkyl, halogen or haloalkyl.

7. The compound according to claim 1, wherein  $R_1$  is pyridyl( $C_{1-4}$ )alkyl.


8. The compound according to claim 7, wherein  $R_2$  is phenoxyphenyl or benzyloxyphenyl, wherein the phenoxy moiety is optionally substituted with alkyl, halogen or haloalkyl.

9. The compound of claim 8, wherein  $R_1$  is pyridylmethyl, pyridylethyl or pyridylpropyl.


10. The compound according to claim 1, wherein  $R_1$  is an optionally substituted piperidin-4-yl.

11. The compound according to claim 10, wherein  $R_1$  is 1-benzylpiperidin-4-yl.

12. The compound according to claim 1, wherein  $R_2$  is




13. The compound according to claim 12, wherein  $R_1$  is



where  $R_3$  and  $R_4$  together form an alkylene chain having 4 to 5 carbon atoms;  $Y$  is an optionally substituted  $C_{1-6}$  alkylene chain.


14. The compound according to claim 12, wherein  $R_1$  is




where  $R_3$  and  $R_4$  are independently hydrogen, alkyl or alkylenearyl, and  $Y$  is an optionally substituted  $C_{1-6}$  alkylene chain.

15. The compound of claims 13 or 14, wherein  $p = 0$ .

16. The compound according to claim 1, wherein  $R_2$  is




17. The compounds according to claim 16, wherein R<sub>1</sub> is



where R<sub>3</sub> and R<sub>4</sub> together form an alkylene chain having 4 to 5 carbon atoms; Y is an optionally substituted C<sub>1-6</sub> alkylene chain.


18. The compound according to claim 16, wherein R<sub>1</sub> is




where R<sub>3</sub> and R<sub>4</sub> are independently hydrogen, alkyl or alkylenaryl, and Y is an optionally substituted C<sub>1-6</sub> alkylene chain.

19. The compound according to claim 16, wherein R<sub>8</sub> is hydrogen.

20. The compound according to claim 1, wherein R<sub>2</sub> is




21. The compound according to claim 20, wherein R<sub>1</sub> is



where R<sub>3</sub> and R<sub>4</sub> together form an alkylene chain having 4 to 5 carbon atoms; Y is an optionally substituted C<sub>1-6</sub> alkylene chain.


22. The compound according to claim 20, wherein R<sub>1</sub> is



where  $R_3$  and  $R_4$  are independently hydrogen, alkyl or alkylenylaryl, and  $Y$  is an optionally substituted  $C_{1-6}$  alkylene chain.


23. The compound according to claim 1, wherein  $R_2$  is naphthalene.

24. The compound according to claim 23, wherein  $R_1$  is



where  $R_3$  and  $R_4$  together form an alkylene chain having 4 to 5 carbon atoms;  $Y$  is an optionally substituted  $C_{1-6}$  alkylene chain.

25. The compound according to claim 23, wherein  $R_1$  is



where  $R_3$  and  $R_4$  are independently hydrogen, alkyl or alkylenylaryl, and  $Y$  is an optionally substituted  $C_{1-6}$  alkylene chain.

26. The compound according to claim 1, wherein said compound is selected from the group consisting of:

3-(2-piperidinylethyl)-2-(3-phenoxyphenyl) thiazolidin-4-one;

( $\pm$ )-3-(2-piperidinylethyl)-2-(2,2-diphenylethenyl) thiazolidin-4-one;

(+)-3-(2-piperidinylethyl)-2-(2,2-diphenylethenyl) thiazolidin-4-one;

(-)-3-(2-piperidinylethyl)-2-(2,2-diphenylethenyl) thiazolidin-4-one;

3-(2-piperidinylethyl)-2-(3-(4-tert-butyloxy)phenyl) thiazolidin-4-one;

3-(2-piperidinylethyl)-2-(2,2-diphenylethenyl) thiazinidin-4-one;

3-(2-piperidinylethyl)-2-(2-(4-chlorophenyl)furan) thiazolidin-4-one;

3-(2-piperidinylethyl)-2-(3-(3,4-dichlorophenoxy)phenyl) thiazolidin-4-one;

3-(2-piperidinylethyl)-2-(3-(3-trifluoromethylphenoxy)phenyl) thiazolidin-4-one;

3-(2-piperidinylethyl)-2-(3-benzyloxyphenyl) thiazolidin-4-one;

3-(2-piperidinylethyl)-2-(3-(4-chlorophenoxy)phenyl) thiazolidin-4-one;

3-(2-piperidinylethyl)-2-(3-(3,5-dichlorophenoxy)phenyl) thiazolidin-4-one;

3-(2-piperidinylethyl)-2-(4-(4-fluorophenoxy)phenyl) thiazolidin-4-one;

3-(2-piperidinylethyl)-2-(3-(4-methoxyphenoxy)phenyl) thiazolidin-4-one;

3-(2-piperidinylethyl)-2-(*N*-ethylcarbozolyl) thiazolidin-4-one;

3-(2-piperidinylethyl)-2-naphthyl thiazolidin-4-one;

3-(2-piperidinylethyl)-2-(2,2-diphenylethenyl) thiazolidin-4-one;

3-(*N,N*-dimethylethylamino)-2-(2,2-diphenylethenyl) thiazolidin-4-one;

3-(*N,N*-dimethylethylamino)-2-(3-(4-tert-butyl)phenoxy)phenyl) thiazolidin-4-one;

3-(2-pyridinylmethyl)-2-(3-(4-tert-butyl)phenoxy)phenyl) thiazolidin-4-one;

3-(*N,N*-dimethylethylamino)-2-(2,2-diphenylethenyl) thiazolidin-4-one;

3-(*N*-benzyl-4-piperidinyl)-2-(3-phenoxyphenyl) thiazolidin-4-one;

3-(3-imidazolylpropyl)-2-(3-benzyloxyphenyl) thiazolidin-4-one;

3-(2-pyridinylmethyl)-2-(3-(3-trifluoromethylphenoxy)phenyl) thiazolidin-4-one;

3-(*N,N*-dimethylethylamino)-2-(3-(3,5-dichlorophenoxy)phenyl) thiazolidin-4-one;

3-(*N,N*-dimethylpropylamino)-2-(3-(3,5-dichlorophenoxy)phenyl) thiazolidin-4-one;

3-(*N*-benzyl-4-piperidinyl)-2-(4-(4-fluorophenoxy)phenyl) thiazolidin-4-one;

3-(2-pyrrolidinylethyl)-2-(3-(3,4-dichlorophenoxy)phenyl) thiazolidin-4-one;

3-(2-pyrrolidinylethyl)-2-(3-(3-trifluoromethylphenoxy)phenyl) thiazolidin-4-one;

3-(2-pyrrolidinylethyl)-2-(*N*-ethylcarbozole) thiazolidin-4-one;

3-(2-pyrrolidinylethyl)-2-(3-benzyloxyphenyl) thiazolidin-4-one;

3-(*N*-ethylmorpholinyl)-2-(3-(3,4-dichlorophenoxy)phenyl) thiazolidin-4-one;

3-(*N,N*-dimethylethylamino)-2-(3-(3,4-dichlorophenoxy)phenyl) thiazolidin-4-one;

3-(*N,N*-dimethylethylamino)-2-(3-(3-trifluoromethylphenoxy)phenyl) thiazolidin-4-one;

3-(3-imidazolylpropyl)-2-(3-(3-trifluoromethylphenoxy)phenyl) thiazolidin-4-one;

3-(*N,N*-dimethylpropylamino)-2-(3-(3-trifluoromethylphenoxy)phenyl) thiazolidin-4-one;

3-(*N*-ethylbenzylamino)-2-(3-(3-trifluoromethylphenoxy)phenyl) thiazolidin-4-one;

3-(*N,N*-diisopropylethylamino)-2-(3-(3-trifluoromethylphenoxy)phenyl) thiazolidin-4-one;

3-(*N,N*-dimethyl-2,2-dimethylpropylamino)-2-(3-(3,4-dichlorophenoxy)phenyl) thiazolidin-4-one;

3-(2-methylpiperidinyl-*N*-propyl)-2-(3-(3,4-dichlorophenoxy)phenyl) thiazolidin-4-one;

3-(*N,N*-dimethyl-2,2-dimethylpropylamino)-2-(3-(3-trifluoromethylphenoxy)phenyl) thiazolidin-4-one; and

3-(2-methylpiperidinyl-*N*-propyl)-2-(3-(3-trifluoromethylphenoxy)phenyl) thiazolidin-4-one.

27. A pharmaceutical composition, comprising the compound of claim 1, and a pharmaceutically acceptable carrier or diluent.

28. A method of making a compound according to claim 1 wherein said method comprises reacting:

(i) an amine having the Formula II:



and

(ii) an aldehyde having the Formula III:



in the presence of a mercapto acid having the Formula IV:



wherein  $\text{R}_1$ ,  $\text{R}_2$  and  $n$  are as defined in claim 1.

29. The method according to claim 28, wherein the reaction is conducted in the presence of toluene.

30. The method according to claim 28, wherein the reaction is conducted in the presence of at least one 4 Angstrom molecular sieve.

31. The method according to claim 28, wherein the reaction is conducted at a temperature of from about 50 °C to about 110 °C.

32. The method according to claim 28, wherein the reaction is conducted for about 2 hours to about 24 hours.

33. A method of treating, preventing or ameliorating a disorder responsive to blockage of sodium channels in a mammal suffering therefrom, comprising administering to a mammal in need of such treatment an effective amount of a compound according to claim 1, or pharmaceutically acceptable salt thereof.

34. The method according to claim 33, wherein said disorder is selected from the group consisting of: neuronal damage; a neurodegenerative condition, acute or chronic pain, depression, and diabetic neuropathy.

35. The method according to claim 33, wherein said neuronal damage is caused by focal or global ischemia.

36. The method according to claim 33, wherein said neurodegenerative condition is amyotrophic lateral sclerosis (ALS).

37. The method according to claim 33 wherein said mammal is a human, dog or cat.

38. A pharmaceutical composition for treatment of a mammal having a disorder or condition responsive to blockage of sodium channels, which comprises an amount of the compound according to claim 1, or a pharmaceutically effective salt thereof, that is effective for treating said disorder or condition, and a pharmaceutically acceptable carrier.

39. The compound according to claim 26, wherein said compound is selected from the group consisting of:

- 3-(2-piperidinylethyl)-2-(3-phenoxyphenyl) thiazolidin-4-one;
- (±)-3-(2-piperidinylethyl)-2-(2,2-diphenylethenyl) thiazolidin-4-one;
- (+)-3-(2-piperidinylethyl)-2-(2,2-diphenylethenyl) thiazolidin-4-one;
- (-)-3-(2-piperidinylethyl)-2-(2,2-diphenylethenyl) thiazolidin-4-one;
- 3-(2-piperidinylethyl)-2-(3-(4-tert-butylphenoxy)phenyl) thiazolidin-4-one;
- 3-(2-piperidinylethyl)-2-(3-(3,4-dichlorophenoxy)phenyl) thiazolidin-4-one;
- 3-(2-piperidinylethyl)-2-(3-(3-trifluoromethylphenoxy)phenyl) thiazolidin-4-one;
- 3-(2-piperidinylethyl)-2-(3-benzyloxyphenyl) thiazolidin-4-one;
- 3-(2-piperidinylethyl)-2-(3-(4-chlorophenoxy)phenyl) thiazolidin-4-one;
- 3-(2-piperidinylethyl)-2-(3-(3,5-dichlorophenoxy)phenyl) thiazolidin-4-one;

3-(2-piperidinylethyl)-2-(4-(4-fluorophenoxy)phenyl) thiazolidin-4-one;  
3-(N-benzyl-4-piperidinyl)-2-(3-phenoxyphenyl) thiazolidin-4-one;  
3-(N-benzyl-4-piperidinyl)-2-(4-(4-fluorophenoxy)phenyl) thiazolidin-4-one;  
3-(2-pyrrolidinylethyl)-2-(3-(3-trifluoromethylphenoxy)phenyl) thiazolidin-4-one;  
3-(N-ethylbenzylamino)-2-(3-(3-trifluoromethylphenoxy)phenyl) thiazolidin-4-one;  
3-(N,N-diisopropylethylamino)-2-(3-(3-trifluoromethylphenoxy)phenyl) thiazolidin-4-one;  
3-(N,N-dimethyl-2,2-dimethylpropylamino)-2-(3-(3,4-dichlorophenoxy)phenyl) thiazolidin-4-one; and  
3-(N,N-dimethyl-2,2-dimethylpropylamino)-2-(3-(3-trifluoromethylphenoxy)phenyl) thiazolidin-4-one.